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Abstract
Purpose—There are scant data available on the relationship between smoking and total prostate 
specific antigen, free prostate specific antigen and percent-free prostate specific antigen. Given the 
high prevalence of smoking and the frequency of prostate specific antigen screening, it is 
important to determine any association between smoking and prostate specific antigen values 
using nationally representative data.
Materials and Methods—Included in the final study population were 3,820 men 40 years old 
or older who participated in the 2001–2006 NHANES (National Health and Nutrition Examination 
Survey) and met the eligibility criteria for prostate specific antigen testing. The distributions of 
total, free and percent free prostate specific antigen were estimated by sociodemographic and 
clinical characteristics. Multivariate linear regression models were fit to determine the adjusted 
relationship between smoking and total and percent free prostate specific antigen while 
simultaneously controlling for these characteristics.
Results—For all ages combined the median total and free prostate specific antigen levels were 
0.90 (0.81– 0.90) and 0.26 (0.25– 0.28) ng/ml, respectively. Multivariate linear regression analysis 
showed that total prostate specific antigen was 7.9% and 12.2% lower among current and former 
smokers, respectively, than among never smokers. High body mass index and diabetes were also 
statistically significantly associated with a lower total prostate specific antigen. Approximately a 
third of the men had a percent free prostate specific antigen less than 25%. Current smokers had a 
significantly lower percent free prostate specific antigen than former smokers.
Conclusions—Our finding that smoking is inversely associated with total prostate specific 
antigen may have potential implications for the interpretation of prostate specific antigen levels in 
men who are current or former smokers. Given the high prevalence of smoking, obesity and 
diabetes, additional research on the combined effect of these health risk factors is warranted.
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Although the mortality benefit from screening with PSA is uncertain,1,2 PSA based 
screening has resulted in a downward stage shift to more organ confined prostate cancer at 
the time of diagnosis.3 The often used PSA cut point of greater than 4.0 ng/ml detects the 
majority of prostate cancers. However, the specificity of the PSA test is low and has led to a 
high rate of false-positive results, particularly among older men with BPH. Percent-free PSA 
(the ratio of fPSA-to-tPSA) testing has been used as an adjunct to PSA tests to enhance the 
specificity and decrease the number of unnecessary biopsies.4
It has been recognized that age, race, BPH, prostate size and prostatitis can influence PSA 
levels.5,6 Epidemiological studies have also shown that PSA can be affected by several 
heath characteristics including obesity, diabetes and certain medications such as NSAIDs, 
statins and thiazide diuretics.7–9 Scant data exist on the association between smoking and 
PSA levels. Gelmann et al reported that current and former smokers had a statistically 
significantly lower PSA and fPSA levels compared with never smokers.10 Gray et al 
measured PSA values in New Zealand Europeans, Maori and Pacific Islanders, and 
concluded that this inverse association was only true for fPSA but not tPSA.11 Kristal et al 
reported that current smokers had lower levels of tPSA than nonsmokers and this inverse 
association was borderline significant.12 While provocative, these studies produced 
inconsistent results because potential confounders such as diabetes, BPH and the use of 
certain medications were not controlled for.
Smoking has been a devastating health concern for decades. In 2010 the U.S. Centers for 
Disease Control and Prevention reported that nearly a quarter of American men 18 years old 
or older, approximately 23 million, were current cigarette smokers in 2009.13 Given the high 
prevalence of smoking and the frequency of PSA screening, it is important to examine the 
associations between smoking and PSA level while controlling for key sociodemographic 
and clinical variables using nationally representative data. Our study may aid in interpreting 
PSA values more accurately, and may have possible implications for the use of tPSA and 
%fPSA in recommending further evaluation of abnormal PSA results with a prostate biopsy.
MATERIALS AND METHODS
Study Population
The NHANES is a nationally representative cross-sectional survey of the adult United States 
noninstitutionalized population. A detailed description of sampling and data collection 
procedures has been published elsewhere.14 The overall response rates for the 2001 to 2002, 
2003 to 2004 and 2005 to 2006 surveys were 84%, 79% and 80% for the interview 
component, and 80%, 76% and 77% for the examination component, respectively.
Men 40 years old or older were eligible for PSA testing consisting of measured tPSA and 
fPSA as well as a calculated %fPSA. For the 2001–2006 NHANES 4,869 men were 40 
years old or older, of whom 4,589 (94.2%) participated in the NHANES physical 
examination. Men were excluded from PSA testing if they reported current infection or 
inflammation of the prostate gland, digital rectal examination in the last week, prostate 
biopsy in the last 30 days, cystoscopy in the last 30 days, history of prostate cancer or if 
information was missing for any of those questions (323, 7.0%). In addition, 339 (7.4%) 
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men refused or did not give permission for the PSA test and 107 (2.3%) eligible men were 
missing PSA values. The final study population included 3,820 of 4,589 or 83.2% of all 
examined men 40 years old or older who participated in the NHANES PSA testing.
Statistical Analysis
Smoking status was defined using cotinine level, and the 2 survey questions, “Have you 
smoked at least 100 cigarettes in your entire life?” and “Do you now smoke cigarettes every 
day, some days or not at all?” Serum cotinine levels greater than 10 ng/ml are associated 
with active smoking within the last few days.15 Respondents with a serum cotinine 
concentration greater than 10 ng/ml or who had smoked at least 100 cigarettes during their 
lifetime and, at the time of interview, reported smoking every day or some days were 
classified as current smokers. Those who responded “not at all” to the latter question were 
classified as former smokers. Finally, respondents who had smoked fewer than 100 
cigarettes in their lifetime were classified as never smokers. Distributions of tPSA, fPSA and 
%fPSA for the 2001–2006 NHANES were estimated by smoking status as well as other 
demographic and clinical characteristics. Of those characteristics race/ethnicity was 
categorized as nonHispanic white, non-Hispanic black, Mexican-American (Mexican or 
Mexican-American) and other (other Hispanic or other race including multiracial), and tPSA 
and fPSA were analyzed as continuous variables. In this study medications included statins, 
thiazide diuretics and NSAIDs. Over the counter NSAIDs were not examined because the 
NHANES questionnaires did not collect this information. In the descriptive analysis %fPSA 
was dichotomized to less than 25% vs 25% or greater since less than 25% is typically the cut 
point for further diagnostic evaluation. Continuous variables were presented as weighted 
medians and discrete variables as weighted percentages. The 95% CIs for the medians were 
determined using the Woodruff method.16 For discrete variables 95% CIs were calculated 
using a logit transformation. No statistical tests were conducted in the bivariate analysis 
because statistical testing for differences in medians was not available in software packages 
for complex sample survey data. CIs around the median were included to provide estimates 
of the variability and allowed for informal comparisons.
Multivariate linear regression models were fit to determine the adjusted relationship between 
smoking status and PSA values (tPSA and %fPSA). Independent variables included age, 
race, BMI, diabetes, BPH and C-reactive protein. We included those medications mentioned 
in the model because previously published studies showed possible associations between 
these medications and PSA.7,17 We excluded a family history of prostate cancer because this 
information was only included in the 2003–2006 NHANES. The linearity assumption for 
continuous predictors was assessed in each model using restricted cubic spline functions.18 
The relationship between C-reactive protein and each PSA outcome was nonlinear, and was 
transformed using a 3-knot restricted cubic spline function. The relationships between the 
other continuous predictors and each PSA outcome were found to be linear. As such, age 
and BMI were treated as linear effects in the final models. The dependent variable, tPSA, 
was log transformed because of nonnormality. Due to the small number of the denominator 
df, the F-statistic with Satterthwaite correction for the df was used to test significance in 
each model. Since tPSA was log transformed, the adjusted associations were presented as 
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the percent change in the tPSA geometric mean. The adjusted associations with %fPSA 
were presented as the absolute change in %fPSA.
Variance estimates were calculated using Taylor series linearization. Sample weights, which 
account for the differential probabilities of selection, nonresponse and noncoverage, were 
incorporated into the variance estimation process. The R Package for Statistical Computing 
was used to estimate the percentiles and corresponding CIs using the Woodruff method.19 
SAS-Callable SUDAAN® version 9.0 and SAS® version 9.2 were used for the remainder of 
the analyses including the regression modeling.
RESULTS
For all ages combined the median (95% CI) tPSA and fPSA was 0.90 (0.81– 0.90) ng/ml 
and 0.26 (0.25–0.28) ng/ml, respectively (table 1). tPSA and fPSA increased with age and 
decreased with increasing BMI. Lower values of tPSA were observed for current smokers 
(0.80 [0.80–0.90] ng/ml) than for former smokers (0.95 [0.83–1.01] ng/ml). The fPSA in 
current smokers (0.24 [0.23– 0.25] ng/ml) was lower than that in former smokers (0.28 
[0.27–0.30] ng/ml) and never smokers (0.27 [0.25– 0.29] ng/ml). Men with BPH had higher 
tPSA and fPSA levels than those without BPH. Overall 34.2% of men had a %fPSA less 
than 25%. Current smokers had a higher %fPSA less than 25% (38.3%) than former 
smokers (31.3%) and never smokers (33.1%). Diabetic men had a higher %fPSA less than 
25% than nondiabetic men. Interestingly we found that %fPSA less than 25% increased with 
increasing C-reactive protein.
The results of the multivariate linear regression model predicting tPSA are shown in table 2. 
The predicted geometric mean of tPSA was 7.9% and 12.2% lower among current and 
former smokers, respectively, compared with never smokers. A 5-year increase in age was 
associated with a significant 13.7% increase in the geometrical mean of tPSA. However, a 5 
kg/m2 increase in BMI was associated with a significant 6.9% decrease in tPSA. Diabetes 
was associated with a 14.8% decrease in tPSA compared with nondiabetics, while BPH was 
associated with a 16.5% increase in tPSA. The predicted geometric mean of tPSA was 
14.1% higher among non-Hispanic black vs nonHispanic white men. Comparing medication 
use and the geometric mean of tPSA, no statistically significant association was found. C-
reactive protein had a significant nonlinear relationship with tPSA.
Results of the multivariate linear regression predicting %fPSA are presented in table 3. 
Current smokers had a statistically significantly lower %fPSA compared with former 
smokers (change in %fPSA −2.4; 95% CI −3.8, −0.9; comparison not shown). Diabetes was 
associated with a higher %fPSA (change in %fPSA 3.8; 95% CI 1.4, 6.2) while increased 
age was associated with a significant decrease in %fPSA (change in %fPSA −0.3; 95% CI 
−0.5, −0.05 for 5-year increase). Mexican-Americans had a lower %fPSA compared with 
nonHispanic whites (change in %fPSA −3.2; 95% CI −4.8, −1.7). There was also a 
significant nonlinear relationship between C-reactive protein and %fPSA.
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Using nationally representative data and adjusting for multiple confounders, we found that 
current and former smokers had a statistically significantly lower tPSA compared with never 
smokers, and current smokers had a significantly lower %fPSA than former smokers. 
Gelmann et al examined the relationship between smoking and PSA using the study cohort 
of the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.10 The authors found 
that tPSA and fPSA levels were significantly lower among current and former smokers, 
respectively, compared with never smokers. Similarly an analysis of the 2001–2002 
NHANES data demonstrated that men who had ever smoked had a lower PSA than those 
who had not.17 The underlying causes for the inverse associations between smoking and 
tPSA levels are largely unknown. It has been reported that male smokers had an increased 
level of circulating sex hormone-binding globulin, which might reduce the synthesis of 
PSA.20 To our knowledge our study finding that current smokers had a significantly lower 
%fPSA than former smokers has not been reported in the literature. Additional research is 
needed to verify this finding.
To date the U.S. Preventive Services Task Force does not recommend or advise against 
routine screening for prostate cancer for men 50 to 74 years old.21,22 The American 
Urological Association recommends starting a discussion about prostate cancer screening 
with men who are at average risk at age 40 years to establish a baseline PSA.23 While 
adjusting for other potential confounders, our study showed that there was an approximate 
8% to 12% decrease in tPSA among current and former smokers. Thus, men who have ever 
smoked are less likely to have an abnormal result on PSA screening and diagnostic biopsy, 
possibly resulting in fewer screen detected prostate cancers than in those who have never 
smoked. In this study we excluded men with prostate cancer, prostatic infection or 
inflammation. In this relatively healthy population the median tPSA was 0.9 ng/ml. Loeb et 
al showed that a baseline PSA between 0.7 and 2.5 ng/ml in men 40 to 49 years old was 
associated with a 14.6-fold increased risk of prostate cancer.24 In addition to the often used 
PSA cut point of greater than 4.0 ng/ml, age specific reference ranges for PSA have been 
demonstrated as a useful approach to improve PSA sensitivity and specificity.25
A survival analysis using data from the National Institutes of Health-American Association 
of Retired Persons Diet and Health Study suggested that current and former smokers might 
be at decreased risk for prostate cancer diagnosis, primarily localized disease.26 A meta-
analysis of 24 cohort studies also suggested that current smokers were not at increased risk 
for incident prostate cancer.27 These findings may be partially attributable to detection bias 
resulting from the inverse relationship between smoking and PSA. If smoking substantially 
alters the relationship between PSA and any potential underlying prostate cancer, we may 
need to modify, according to smoking status, the often used PSA cutoff points that signal the 
necessity of further evaluation with prostate biopsy. Such a modification may help to 
interpret screening results more accurately.
Biologically the mechanisms of initiating or accelerating prostate cancer by smoking have 
been postulated, including exposure to carcinogenic compounds, modulation of male 
hormones and genetic mutations in suppressor genes.28 Despite the demonstrated links 
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between smoking and several types of solid tumors, the role of smoking in the development 
of prostate cancer is inconclusive. However, studies have consistently shown that current 
smokers have an increased risk of fatal prostate cancer.27,29 Delayed detection of prostate 
cancer due to the effects of smoking on PSA may contribute in part to worse health 
outcomes of prostate cancer among smokers.
It has been widely reported that obesity and diabetes have inverse associations with PSA 
levels.8,9,11 These findings were also confirmed by our study. Interestingly we did not find 
any statistically significant association between PSA and the use of NSAIDs, statins or 
thiazide diuretics as found by Chang et al.7 Different ways of defining smoking status, and 
various sociodemographic, clinical factors and medications examined in these 2 studies may 
partially account for this difference. Although inverse associations between PSA and the use 
of NSAIDs and statins have been reported,7,17 a recent study suggested that use of NSAIDs 
(excluding aspirin) and statins was not associated with PSA, and only aspirin users had a 
statistically significantly lower PSA than nonusers among men who had never smoked.30
A major strength of this study is that it was based on nationwide, population based sampling 
survey data. However, it has at least 3 limitations. 1) Smoking status was defined based on 
self-report and serum cotinine levels. Self-report smoking status was subject to 
misclassification errors. The use of cotinine level in defining current smokers should help 
reduce the misclassification of self-reported smoking status. 2) This study was cross-
sectional, and the temporal relationship of associations between smoking and PSA cannot be 
assessed. 3) The NHANES did not collect information on nonprescription medication use so 
the effects of any nonprescription medications cannot be examined.
CONCLUSIONS
Men who had ever smoked had an 8% to 12% decrease in tPSA compared with those who 
had never smoked. Although the magnitude of the inverse association between smoking 
status and PSA alone may not be substantial, the joint effect of smoking, obesity and 
diabetes associated with PSA may have greater clinical implications given the high 
prevalence of these conditions. Additional research on the combined effect of these and 
other health risk factors on PSA is needed. Further studies to better understand the biological 
role of smoking in the development of prostate cancer are also warranted.
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fPSA free prostate specific antigen
NSAIDs nonsteroidal anti-inflammatory drugs
PSA prostate specific antigen
tPSA total prostate specific antigen
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Table 1
PSA levels by study population characteristics
Sample Size Median ng/ml tPSA (95% 
CI)
Median ng/ml fPSA (95% 
CI)
Median %fPSA Less Than 
25% (95% CI)
Total 3,820 0.90 (0.81–0.90) 0.26 (0.25–0.28) 34.2 (31.6–36.9)
Age:
  40–49 1,115 0.70 (0.70–0.75) 0.21 (0.20–0.23) 31.8 (28.5–35.3)
  50–59 827 0.90 (0.80–0.95) 0.26 (0.24–0.27) 35.3 (31.9–38.9)
  60–69 840 1.20 (1.08–1.35) 0.33 (0.31–0.36) 39.2 (34.8–43.8)
  70+ 1,038 1.70 (1.58–1.90) 0.48 (0.45–0.52) 32.8 (28.2–37.9)
Race/ethnicity:
  NonHispanic white 2,205 0.90 (0.80–0.94) 0.27 (0.25–0.28) 33.6 (30.9–36.5)
  NonHispanic black 709 0.90 (0.80–1.00) 0.27 (0.25–0.30) 34.0 (29.9–38.4)
  Mexican-American 695 0.90 (0.80–0.97) 0.24 (0.22–0.25) 40.1 (34.8–45.7)
  Other 211 0.80 (0.70–1.00) 0.24 (0.20–0.28) 36.7 (26.3–48.4)
Family history of prostate Ca:*
  No 2,073 0.85 (0.80–0.90) 0.26 (0.25–0.27) 31.7 (28.8–34.7)
  Yes 199 0.97 (0.73–1.30) 0.31 (0.25–0.35) 31.0 (23.9–39.1)
Smoking status:
  Current smoker 1,188 0.80 (0.80–0.90) 0.24 (0.23–0.25) 38.3 (34.6–42.1)
  Former smoker 1,359 0.95 (0.83–1.01) 0.28 (0.27–0.30) 31.3 (27.3–35.6)
  Never smoker 1,270 0.90 (0.80–0.94) 0.27 (0.25–0.29) 33.1 (29.4–37.0)
BMI (kg/m2):
  Normal (less than 25) 905 1.00 (0.90–1.10) 0.30 (0.28–0.33) 35.2 (31.2–39.3)
  Overweight (25–less than 30) 1,621 0.90 (0.80–0.95) 0.27 (0.25–0.28) 33.5 (30.2–36.9)
  Obese (30+) 1,187 0.80 (0.76–0.89) 0.25 (0.23–0.25) 34.3 (30.2–38.6)
Diabetes:
  No 3,253 0.90 (0.84–0.91) 0.26 (0.25–0.27) 35.0 (32.4–37.7)
  Yes 564 0.80 (0.73–0.90) 0.27 (0.25–0.29) 27.7 (21.7–34.5)
BPH:
  No 3,114 0.86 (0.80–0.90) 0.26 (0.25–0.27) 33.7 (30.9–36.6)
  Yes 468 1.27 (1.00–1.50) 0.35 (0.33–0.38) 37.9 (31.5–44.9)
Statin use:
  No 2,900 0.90 (0.80–0.90) 0.26 (0.25–0.27) 34.4 (31.3–37.7)
  Yes 769 0.97 (0.83–1.00) 0.28 (0.26–0.30) 33.6 (29.4–38.1)
NSAID use:†
  No 3,419 0.90 (0.82–0.90) 0.26 (0.25–0.27) 34.2 (31.6–36.9)
  Yes 401 0.90 (0.74–1.00) 0.28 (0.26–0.30) 34.4 (27.8–41.7)
Thiazide diuretic use:
  No 3,426 0.90 (0.80–0.90) 0.26 (0.25–0.27) 34.9 (32.2–37.6)
  Yes 394 1.00 (0.82–1.10) 0.29 (0.25–0.33) 27.7 (21.1–35.5)
Cotinine level (ng/ml):













Li et al. Page 10
Sample Size Median ng/ml tPSA (95% 
CI)
Median ng/ml fPSA (95% 
CI)
Median %fPSA Less Than 
25% (95% CI)
  10 or Less 2,668 0.90 (0.86–1.00) 0.28 (0.26–0.29) 32.7 (29.8–35.8)
  Greater than 10 1,142 0.80 (0.78–0.90) 0.24 (0.22–0.25) 37.6 (33.8–41.6)
C-reactive protein (mg/dl):
  Less than 1.0 3,499 0.90 (0.80–0.90) 0.26 (0.25–0.27) 33.6 (31.0–36.3)
  1.0–3.0 261 0.84 (0.73–1.15) 0.25 (0.22–0.31) 40.1 (31.9–48.9)
  Greater than 3.0 60 1.16 (1.00–1.40) 0.30 (0.21–0.40) 53.7 (36.3–70.3)
*
Only available for the NHANES 2003–2006.
†
Prescription only.
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Table 2
Multivariate model predicting geometric mean of tPSA
% Change in Predicted Geometric
Mean (95% CI) p Value*
Age (per 5-yr increase) 13.7 (12.1, 15.4) <0.001
Race/ethnicity: 0.098
  NonHispanic white 0 (reference)
  NonHispanic black 14.1 (3.8, 25.3)
  Mexican-American 10.1 (−0.7, 22.1)
  Other 0.4 (−13.7, 16.7)
Smoking status: 0.015
  Current smoker −7.9 (−15.1, −0.1)
  Former smoker −12.2 (−20.5, −3.0)
  Never smoker 0 (reference)
BMI (per 5 kg/m2 increase) −6.9 (−9.3, −4.4) <0.001
Diabetes: 0.003
  No 0 (reference)
  Yes −14.8 (−23.2, −5.4)
BPH: 0.016
  No 0 (reference)
  Yes 16.5 (3.1, 31.7)
Statin use: 0.274
  No 0 (reference)
  Yes −4.3 (−11.6, 3.6)
NSAID use:† 0.217
  No 0 (reference)
  Yes −6.3 (−15.6, 4.0)
Thiazide diuretic use: 0.470
  No 0 (reference)
  Yes −4.6 (−16.1, 8.6)
C-reactive protein‡ Nonlinear (nonlinear) 0.001
All variables included in the model are shown in the table.
*
Based on the F-statistic with Satterthwaite correction for the degrees of freedom from the simultaneous test that all coefficients for a given 




Increasing C-reactive protein was associated with higher tPSA for C-reactive protein values up to 0.6 mg/dl. Above this level C-reactive protein 
did not have a significant effect on tPSA.
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Table 3
Multivariate model predicting % fPSA
Change in Predicted %fPSA
Mean (95% CI) p Value*
Age (per 5-yr increase) −0.3 (−0.5, −0.05) 0.021
Race/ethnicity: 0.048
  NonHispanic white 0 (reference)
  NonHispanic black −0.4 (−1.8, 0.9)
  Mexican-American −3.2 (−4.8, −1.7)
  Other −1.3 (−4.4, 1.7)
Smoking status: 0.015
  Current smoker −1.2 (−2.8, 0.4)
  Former smoker 1.2 (−0.1, 2.5)
  Never smoker 0 (reference)
BMI (per 5 kg/m2 increase) 0.0 (−0.6, 0.5) 0.926
Diabetes: 0.003
  No 0 (reference)
  Yes 3.8 (1.4, 6.2)
BPH: 0.145
  No 0 (reference)
  Yes −1.4 (−3.4, 0.5)
Statin use: 0.812
  No 0 (reference)
  Yes −0.2 (−1.6, 1.2)
NSAID use:† 0.287
  No 0 (reference)
  Yes 1.2 (−1.0, 3.4)
Thiazide diuretic use: 0.151
  No 0 (reference)
  Yes 1.5 (−0.6, 3.7)
C-reactive protein‡ Nonlinear (nonlinear) <0.001
All variables included in the model are shown in the table.
*
Based on the F-statistic with Satterthwaite correction for the degrees of freedom from the simultaneous test that all coefficients for a given 




Increasing C-reactive protein was associated with a decrease in %fPSA for levels up to 0.7 mg/dl. Above this level there was no relationship 
between C-reactive protein and %fPSA.
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